10 November 2023 - It’s been one year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with ...
18 August 2023 - CADTH is establishing an industry task force that will build upon the recently released guidance for reporting ...
24 May 2023 - The Public Summary Document of the PBAC's consideration of the interim report of the post-market review of ...
20 January 2023 - Consultation on a revised draft of the PBS post-market review framework was open from 20 October ...
22 December 2022 - The final report for the post-market review of medicines for smoking cessation is now available. The ...
29 November 2022 - The Department of Health and Aged Care has received a request to extend the consultation period on ...
20 October 2022 - The Department of Health and Aged Care is inviting stakeholders to provide feedback on a revised ...
1 September 2022 - CADTH is pleased to announce the launch of its new post-market drug evaluation program. ...
8 August 2022 - CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation Network. ...
10 June 2022 - CADTH is pleased to announce the four successful core network partners of its inaugural post-market drug ...
4 February 2022 - CADTH is pleased to announce it is expanding its expertise in the management of pharmaceuticals in ...
3 February 2022 - A stakeholder consultation forum for the post-market review of opiate dependence treatment program medicines will be ...
12 November 2021 - In June 2021, the Drug Utilisation Sub-Committee and the Economics Sub-Committee of the PBAC considered the report ...
17 August 2021 - The public consultation process for the post-market review of opiate dependence treatment program medicines is now ...
5 July 2021 - This project has been established to enhance the adverse event reporting processes. ...